NMRA-511将阿尔茨海默氏症的激动平均减少15.7个百分点, Neumora Therapeutics reports promising Phase 1b results for NMRA-511, reducing Alzheimer’s-related agitation by 15.7 points on average with no serious side effects.

在阿尔茨海默病相关激动症的成年人中,Neumora Therapeutics报告了 NMRA- 511,一个口服的血管压素1a受体对抗剂的积极的1b期结果. Neumora Therapeutics reported positive Phase 1b results for NMRA-511, an oral vasopressin 1a receptor antagonist, in adults with Alzheimer’s-related agitation. 该药物显示,在CMAI规模上,激动症状减少了15.7点,对基线焦虑程度较高的患者的影响更大,并且在没有镇静剂或严重不良事件的情况下得到了良好治疗。 The drug showed a 15.7-point reduction in agitation symptoms on the CMAI scale, with stronger effects in patients with higher baseline anxiety, and was well-tolerated with no sedation or serious adverse events. 该公司计划在2026年进行高剂量试验,并在研究的早期阶段继续发展。 The company plans to advance to higher-dose trials in 2026 and continue development despite the study’s early stage.